About Healx
Healx is a company based in Cambridge (United Kingdom) founded in 2014 by David Brown, Tim Guilliams, and Nick Sireau. Healx has raised $115.37 million across 6 funding rounds from investors including Atomico, Balderton Capital and R42 Group. The company has 80 employees as of December 31, 2021. Healx offers products and services including AI Drug Discovery Platform and Drug Pipeline. Healx operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Cambridge, United Kingdom
- Employees 80 as on 31 Dec, 2021
- Founders David Brown, Tim Guilliams, Nick Sireau
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Healx Limited
- Date of Incorporation 30 Apr, 2014
- Jurisdiction CAMBRIDGE, ENGLAND
-
Annual Revenue
$412.68 (USD)0as on Dec 31, 2021
-
Net Profit
-$21.57 K (USD)-95as on Dec 31, 2021
-
EBITDA
Not available
-
Total Equity Funding
$115.37 M (USD)
in 6 rounds
-
Latest Funding Round
$47 M (USD), Series C
Aug 01, 2024
-
Investors
Atomico
& 11 more
-
Employee Count
80
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Healx
Healx offers a comprehensive portfolio of products and services, including AI Drug Discovery Platform and Drug Pipeline.
Uses AI to identify and repurpose compounds for rare disease treatments
Manages programs for developing new therapies for rare diseases
People of Healx
Unlock access to complete
Unlock access to complete
Funding Insights of Healx
Healx has successfully raised a total of $115.37M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $47 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Healx
Healx has secured backing from 12 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Atomico, Balderton Capital and R42 Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech-based companies are invested in by Atomico venture capital fund.
|
Locked | Locked | Locked | |
|
Tech startups are funded by R42 Group venture capital.
|
Locked | Locked | Locked | |
|
Multistage venture capital investments are focused on technology sectors.
|
Locked | Locked | Locked |
Investor details for Healx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Healx
Investment portfolio details for Healx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Healx
Detailed financials for Healx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Healx Comparisons
Peer comparison for Healx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Healx
Healx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
Detailed competitors of Healx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Healx
Complete news archive for Healx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Healx
Healx was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Healx is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Tim Guilliams is the current CEO of Healx. They have also founded this company.
Healx is a funded company, having raised a total of $115.37M across 6 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Healx is 80.
Annual revenue of Healx is $412.68 as on Dec 31, 2021.
Healx was founded in 2014 in Cambridge, United Kingdom, and operates in the biotechnology sector. An AI-driven platform is utilized to identify treatments for rare diseases, with a pipeline targeting conditions such as Fragile X syndrome, autosomal dominant polycystic kidney disease, chronic pancreatitis, and facioscapulohumeral muscular dystrophy. Operations focus on advancing novel drug candidates through computational methods and clinical development.
Healx's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Healx offers AI Drug Discovery Platform and Drug Pipeline.
Healx has 12 investors. Key investors include Atomico, Balderton Capital, R42 Group, BtoV, and Global Brain.